DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles
- 1 September 2008
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6 (9), 1542-1549
- https://doi.org/10.1111/j.1538-7836.2008.03064.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic DiseasesArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Characteristics of Gastrointestinal Absorption of DX-9065a, a New Synthetic AnticoagulantDrug Metabolism and Pharmacokinetics, 2007
- First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS TrialJournal of Thrombosis and Haemostasis, 2004
- Discovery and characterization of a potent and selective non-amidine inhibitor of human factor XaBiochemical Pharmacology, 2003
- Antithrombotic Effects of DX-9065a, a Direct Factor Xa InhibitorThrombosis and Haemostasis, 2002
- State-of-the-Art Review: Anticoagulation: The Present and FutureClinical and Applied Thrombosis/hemostasis, 2001
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Antithrombotic and Hemorrhagic Effects of DX-9065a, a Direct and Selective Factor Xa Inhibitor: Comparison with a Direct Thrombin Inhibitor and Antithrombin Ill-Dependent AnticoagulantsThrombosis and Haemostasis, 1997
- The coagulation cascade: initiation, maintenance, and regulationBiochemistry, 1991
- HeparinNew England Journal of Medicine, 1991